Information  X 
Enter a valid email address

Basilea Pharmaceutica AG (0QNA)

  Print      Mail a friend

Thursday 02 May, 2019

Basilea Pharmaceutica AG

Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada

Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada

Basel, Switzerland, May 02, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Avir Pharma Inc. (“Avir Pharma”) has launched the antifungal Cresemba® (isavuconazole) in Canada.

David Veitch, Chief Executive Officer, said: “We are very pleased with the launch of Cresemba in Canada. We look forward to Avir Pharma making Cresemba available to patients in Canada as an important new treatment option for potentially life-threatening invasive mold infections. Through our global partnerships Cresemba is already available in more than 25 countries worldwide.”

In June 2017 Basilea entered into a distribution and license agreement with Avir Pharma for both Cresemba and the hospital antibiotic Zevtera (ceftobiprole). Basilea supplies Avir Pharma with products at a transfer price. The granting of the regulatory approval for Cresemba in Canada triggered an undisclosed regulatory milestone payment to Basilea and Basilea is eligible to receive further sales milestone payments.

About Cresemba (isavuconazole)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. Cresemba is approved in Canada for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis.1 Cresemba is also approved in the United States, the European Union and several additional countries in and outside of Europe. It has U.S. and European orphan drug designation for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa (MENA) region, Canada, Russia, Turkey and Israel.2

About Basilea

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102
[email protected]
[email protected]

This press release can be downloaded from www.basilea.com.

References

1    CresembaTM (isavuconazole) Product Monograph: Avir Pharma Inc., December 24, 2018 (http://avirpharma.com/pdf/Product-Monograph-Cresemba.pdf)

2    The registration status and approved indications may vary from country to country.

Attachments


a d v e r t i s e m e n t